¿Cómo se comparó el EPS reciente de IBO con las expectativas?
¿Cómo fue el desempeño de los ingresos de Impact Biomedical Inc IBO en el último trimestre?
¿Cuál es la estimación de ingresos para Impact Biomedical Inc?
¿Cuál es la puntuación de calidad de ganancias de Impact Biomedical Inc?
¿Cuándo informa Impact Biomedical Inc sus ganancias?
¿Cuáles son las ganancias esperadas de Impact Biomedical Inc?
¿Superó Impact Biomedical Inc las expectativas de ganancias?
Estadísticas clave
Cierre Anterior
$0.4515
Precio de apertura
$0.466
Rango del día
$0.4482 - $0.4661
Rango de 52 semanas
$0.3621 - $6.17
Volumen
34.4K
Volumen promedio
142.7K
EPS (TTM)
-3.58
Rendimiento de dividendos
--
Cap. de mercado
$47.9M
¿Qué es IBO?
Impact BioMedical, Inc. is a holding company, which engages in the discovery and development of products and treatment options in specialty biopharmaceuticals and consumer healthcare. The company is headquartered in Houston, Texas and currently employs 2 full-time employees. The company went IPO on 2024-09-16. The company discovers, confirms, and patents science and technologies, which can be developed into new offerings in biopharmaceuticals and consumer healthcare and wellness in collaboration with external partners through research, licensing, co-development, joint ventures, and other relationships. The company has several technologies that are in continuing development, which include Linebacker, Laetose, Functional Fragrance Formulation (3F), Equivir/Equivir G, and Celios. Linebacker is a platform of small molecule electrophilically enhanced polyphenol compounds with potential application in oncology (solid tumors), inflammatory disorders, and neurology. Laetose technology is derived from a combination of multiple sugars independently with myo-inositol. 3F is a suite of organic functional fragrances. Celios is an air purification technology. The company also evaluates additional technologies.